Home    Back

Mefloquine    (DrugBank: Mefloquine)

2 diseases
IDDisease name (Link within this page)Number of trials
25Progressive multifocal leukoencephalopathy7
46Malignant rheumatoid arthritis1

25. Progressive multifocal leukoencephalopathy    [ 23 clinical trials,   33 drugs,   (DrugBank: 20 drugs),   7 drug target genes,   36 drug target pathways]
Searched query = "Progressive multifocal leukoencephalopathy", "PML", "Leukoencephalopathy, progressive multifocal"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
7 / 23 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1JPRN-UMIN000022151
2016/04/3030/04/2016The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathyThe efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy - The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathymefloquine is to be taken orally 275mg for 3days then 275mg weekly for 6 manthsDepartment of Neurology, Shimane University HospitalNULLComplete: follow-up complete20years-oldNot applicableMale and Female5Not selectedJapan
2JPRN-UMIN000023752
2016/04/1424/08/2016Medication with mefloquine hydrochloride for progressive multifocal leukoencephalopathy (PML) out of the application range of insurance progressive multifocal leukoencephalopathyOral mefloquine hydrochloride 275mg once a day at first 3 days.
Since second week, 275mg in each week oral intake until 6 months		Nagoya City UniversityNULLComplete: follow-up completeNot applicableNot applicableMale and Female1Not applicableJapan
3EUCTR2008-001314-24-IT
(EUCTR)		15/01/200919/03/2009A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) - NDA Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) - ND Progressive Multifocal Leukoencephalopathy (PML)
MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy		Trade Name: Lariam
INN or Proposed INN: Mefloquine		BIOGEN IDEC LTDNULLNot RecruitingFemale: yes
Male: yes		40United Kingdom;France;Spain;Italy
4EUCTR2008-001314-24-GB
(EUCTR)		02/01/200928/05/2008A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) Progressive Multifocal Leukoencephalopathy (PML)
MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy		Trade Name: Lariam
Product Name: Mefloquine
Product Code: 111JC101
INN or Proposed INN: MEFLOQUINE		Biogen Idec LtdNULLNot RecruitingFemale: yes
Male: yes		60United Kingdom;France;Spain;Italy
5NCT00746941
(ClinicalTrials.gov)		January 20093/9/2008Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects With Progressive Multifocal Leukoencephalopathy (PML)Progressive Multifocal LeukoencephalopathyDrug: mefloquineBiogenElan PharmaceuticalsTerminated18 Years75 YearsAll37Phase 1;Phase 2United States;Brazil;Germany;Italy;Spain;Australia;France;Puerto Rico;United Kingdom
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6EUCTR2008-001314-24-ES
(EUCTR)		19/11/200811/07/2008A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)Estudio aleatorizado con evaluador en condiciones de ciego para explorar el efecto de mefloquina en sujetos con leucoencefalopatía multifocal progresiva (LMP)A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)Estudio aleatorizado con evaluador en condiciones de ciego para explorar el efecto de mefloquina en sujetos con leucoencefalopatía multifocal progresiva (LMP) Progressive Multifocal Leukoencephalopathy (PML)Leucoencefalopatía Multifocal Progresiva (LMP)
MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy		Trade Name: Lariam
Product Name: Mefloquine
Product Code: 111JC101
INN or Proposed INN: MEFLOQUINE		Biogen Idec LtdNULLNot RecruitingFemale: yes
Male: yes		40United Kingdom;France;Spain;Italy
7EUCTR2008-001314-24-FR
(EUCTR)		22/10/200823/07/2008A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) Progressive Multifocal Leukoencephalopathy (PML)
MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy		Trade Name: Lariam
Product Name: Mefloquine
Product Code: 111JC101
INN or Proposed INN: MEFLOQUINE		Biogen Idec LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		40United Kingdom;France;Spain;Italy

Back to top


46. Malignant rheumatoid arthritis    [ 4,183 clinical trials,   2,538 drugs,   (DrugBank: 401 drugs),   183 drug target genes,   219 drug target pathways]
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 4,183 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2005-002421-31-DE
(EUCTR)		20/10/200503/11/2005A phase II randomised, double-blind, multicenter, placebo-controlled, dose-ranging, parallel group study to compare the efficacy, safety and tolerability of 3 strengths of AD 452 in adult subjects with active rheumatoid arthritis who are currently taking methotrexate. - Efficacy, safety and tolerability of AD 452 in patients wih RAA phase II randomised, double-blind, multicenter, placebo-controlled, dose-ranging, parallel group study to compare the efficacy, safety and tolerability of 3 strengths of AD 452 in adult subjects with active rheumatoid arthritis who are currently taking methotrexate. - Efficacy, safety and tolerability of AD 452 in patients wih RA The purpose of this clinical trial is to evaluate the clinical efficacy, safety and tolerability of three doses of AD 452 in comparison with placebo in the treatment of subjects with active rheumatoid arthritis.
MedDRA version: 7.0;Level: PT;Classification code 10039073		Product Name: AD 452
INN or Proposed INN: (+) isomer of racemic mefloquine
Other descriptive name: (+)erythromefloquine
Product Name: AD 452
INN or Proposed INN: (+) isomer of racemic mefloquine
Other descriptive name: (+) erythromefloquine
Product Name: AD 452
INN or Proposed INN: (+) isomer or racemic mefloquine
Other descriptive name: (+) erythromefloquine		Arakis Ltd.NULLNot RecruitingFemale: yes
Male: yes		292Phase 2United Kingdom;Germany

Back to top